Abstract
DB-1310, a HER3-targeting antibody-drug conjugate, has synergistic anti-tumor activity with trastuzumab in HER2- and HER3-expressing breast cancer.
Published Version (
Free)
Join us for a 30 min session where you can share your feedback and ask us any queries you have